Literature DB >> 32068788

Easy One-Step Amplification and Labeling Procedure for Copy Number Variation Detection.

Sebastián Blesa1, María D Olivares2, Andy S Alic2, Alicia Serrano3,4, Verónica Lendinez1, Verónica González-Albert1, Laura Olivares1, Sergio Martínez-Hervás5, José M Juanes1, Pablo Marín6, Jose T Real5,7, Blanca Navarro3,4, Ana B García-García1,8, Felipe J Chaves1,2,8, Carmen Ivorra2.   

Abstract

BACKGROUND: The specific characteristics of copy number variations (CNVs) require specific methods of detection and characterization. We developed the Easy One-Step Amplification and Labeling procedure for CNV detection (EOSAL-CNV), a new method based on proportional amplification and labeling of amplicons in 1 PCR.
METHODS: We used tailed primers for specific amplification and a pair of labeling probes (only 1 labeled) for amplification and labeling of all amplicons in just 1 reaction. Products were loaded directly onto a capillary DNA sequencer for fragment sizing and quantification. Data obtained could be analyzed by Microsoft Excel spreadsheet or EOSAL-CNV analysis software. We developed the protocol using the LDLR (low density lipoprotein receptor) gene including 23 samples with 8 different CNVs. After optimizing the protocol, it was used for genes in the following multiplexes: BRCA1 (BRCA1 DNA repair associated), BRCA2 (BRCA2 DNA repair associated), CHEK2 (checkpoint kinase 2), MLH1 (mutL homolog 1) plus MSH6 (mutS homolog 6), MSH2 (mutS homolog 2) plus EPCAM (epithelial cell adhesion molecule) and chromosome 17 (especially the TP53 [tumor protein 53] gene). We compared our procedure with multiplex ligation-dependent probe amplification (MLPA).
RESULTS: The simple procedure for CNV detection required 150 min, with <10 min of handwork. After analyzing >240 samples, EOSAL-CNV excluded the presence of CNVs in all controls, and in all cases, results were identical using MLPA and EOSAL-CNV. Analysis of the 17p region in tumor samples showed 100% similarity between fluorescent in situ hybridization and EOSAL-CNV.
CONCLUSIONS: EOSAL-CNV allowed reliable, fast, easy detection and characterization of CNVs. It provides an alternative to targeted analysis methods such as MLPA. © American Association for Clinical Chemistry 2020.

Entities:  

Keywords:  Lynch syndrome; Mutation detection system; copy number variations; familial hypercholesterolemia; genetic diagnosis; hereditary breast cancer

Year:  2020        PMID: 32068788     DOI: 10.1093/clinchem/hvaa002

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  A three-year follow-up study evaluating clinical utility of exome sequencing and diagnostic potential of reanalysis.

Authors:  Jasmine L F Fung; Mullin H C Yu; Shushu Huang; Claudia C Y Chung; Marcus C Y Chan; Sander Pajusalu; Christopher C Y Mak; Vivian C C Hui; Mandy H Y Tsang; Kit San Yeung; Monkol Lek; Brian H Y Chung
Journal:  NPJ Genom Med       Date:  2020-09-10       Impact factor: 8.617

2.  A Very Rare Variant in SREBF2, a Possible Cause of Hypercholesterolemia and Increased Glycemic Levels.

Authors:  Ana-Bárbara García-García; Sergio Martínez-Hervás; Santiago Vernia; Carmen Ivorra; Inés Pulido; Juan-Carlos Martín-Escudero; Marta Casado; Julián Carretero; José T Real; Felipe Javier Chaves
Journal:  Biomedicines       Date:  2022-05-19

3.  Srebf2 Locus Overexpression Reduces Body Weight, Total Cholesterol and Glucose Levels in Mice Fed with Two Different Diets.

Authors:  Irene Andrés-Blasco; Sebastian Blesa; Ángela Vinué; Herminia González-Navarro; José Tomás Real; Sergio Martínez-Hervás; Julián Carretero; Antonio Ferrández-Izquierdo; Felipe Javier Chaves; Ana-Bárbara García-García
Journal:  Nutrients       Date:  2020-10-14       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.